Yungjin Pharm Co Ltd (003520.KS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · South Korea · ISIN KR7003520004
Yungjin Pharm Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 252.04 bn KRW | 254.26 bn KRW |
| Gross profit | 80.35 bn KRW | 77.16 bn KRW |
| Operating income | 8.72 bn KRW | 4.82 bn KRW |
| EBIT | 8.16 bn KRW | 3.97 bn KRW |
| Net income | 1.23 bn KRW | -227.66 m KRW |
| Diluted EPS – continuing operations | 6.74 KRW | -1.24 KRW |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Yungjin Pharm Co Ltd
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. operates as a subsidiary of KT&G Corporation.
More stocks
- Kuang Hong Arts Management (6596.TWO)
- Klingelnberg AG (KLIN.SW)
- EASYCARD Corporation (6035.TWO)
- S.Kijchai Enterprise Public Company Limited (SKN.BK)
- OptimumBank Holdings, Inc. (OPHC)
- UVAT Technology Co Ltd (3580.TWO)
- Devyser Diagnostics AB (DVYSR.ST)
- Hana Pharm Co Ltd (293480.KS)
- Kulmbacher Brauerei (KUL.MU)
- Rainier Acquisition Corporation Class A Ordinary Shares (RNAQ)
- Elensys Co.,Ltd. (264850.KQ)
- Samyang Packaging (272550.KS)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.